Corvus Pharmaceuticals (CRVS) Valuation Check After A Sharp Biotech Share Price Surge

Simply Wall St.02-09

AdvertisementMarket context and recent performance Corvus Pharmaceuticals (CRVS) has drawn investor attention after a sharp share price move, with the stock up 7.35% in the latest session and posting ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2610663331?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-02-09 15:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610663331","market":"nz","top_or_hot":-1,"title":"Corvus Pharmaceuticals (CRVS) Valuation Check After A Sharp Biotech Share Price Surge","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementMarket context and recent performance Corvus Pharmaceuticals (CRVS) has drawn investor attention after a sharp share price move, with the stock up 7.35% in the latest session and posting ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crvs/corvus-pharmaceuticals/news/corvus-pharmaceuticals-crvs-valuation-check-after-a-sharp-bi\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Corvus Pharmaceuticals (CRVS) Valuation Check After A Sharp Biotech Share Price Surge</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCorvus Pharmaceuticals (CRVS) Valuation Check After A Sharp Biotech Share Price Surge\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-09 15:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crvs/corvus-pharmaceuticals/news/corvus-pharmaceuticals-crvs-valuation-check-after-a-sharp-bi><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementMarket context and recent performance Corvus Pharmaceuticals (CRVS) has drawn investor attention after a sharp share price move, with the stock up 7.35% in the latest session and posting ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crvs/corvus-pharmaceuticals/news/corvus-pharmaceuticals-crvs-valuation-check-after-a-sharp-bi\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crvs/corvus-pharmaceuticals/news/corvus-pharmaceuticals-crvs-valuation-check-after-a-sharp-bi","article_id":"2610663331","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crvs/corvus-pharmaceuticals/news/corvus-pharmaceuticals-crvs-valuation-check-after-a-sharp-bi","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2610663331","pubTimestamp":1770620910,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Market context and recent performance\nCorvus Pharmaceuticals (CRVS) has drawn investor attention after a sharp share price move, with the stock up 7.35% in the latest session and posting significant gains over the past month.\nSee our latest analysis for Corvus Pharmaceuticals.\nThe latest move sits within a very strong run, with a 30 day share price return of 201.33% and year to date share price return of 179.51%. The 1 year total shareholder return of 306.76% and very large 3 year total...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","CRVS":"Corvus Pharmaceuticals, Inc.","BK4588":"碎股","BK4139":"生物科技","LABU":"三倍做多标普生物-Direxion","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK4568":"美国抗疫概念"},"translate_title":"生物技术股价大幅飙升后Corvus Pharmaceuticals(CRVS)估值检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"CRVS":1.5,"LABU":1.5},"content_text":"AdvertisementMarket context and recent performance Corvus Pharmaceuticals (CRVS) has drawn investor attention after a sharp share price move, with the stock up 7.35% in the latest session and posting significant gains over the past month. See our latest analysis for Corvus Pharmaceuticals. The latest move sits within a very strong run, with a 30 day share price return of 201.33% and year to date share price return of 179.51%. The 1 year total shareholder return of 306.76% and very large 3 year total shareholder return suggest sentiment around Corvus Pharmaceuticals has shifted sharply, even after today’s 7.35% daily gain to $20.46. If this kind of biotech volatility has your attention, it could be a good moment to see what else is moving and check out 26 healthcare AI stocks as a starting list of ideas. With Corvus still loss making, trading at $20.46 and sitting at what looks like a large discount to a US$33.33 analyst target and intrinsic estimates, you have to ask: is there still a buying opportunity here, or is the market already pricing in future growth? Preferred Price-to-Book of 23.9x: Is it justified? Corvus Pharmaceuticals is currently trading on a P/B of 23.9x, which looks rich when you compare it to both the US Biotechs industry and its direct peers. The price to book ratio compares the company’s market value to its net assets. A higher P/B usually reflects strong optimism about future prospects or valuable intangible assets. For a business that is still loss making and reports no meaningful revenue, a P/B this high suggests the market is placing a lot of weight on the pipeline and future potential rather than current financials. Against the wider US Biotechs industry average P/B of 2.6x and a peer average of 4.4x, Corvus stands out as materially more expensive on this metric. That gap is large, so any change in sentiment around its trial programs or funding needs could matter a lot for how comfortably this valuation sits. See what the numbers say about this price — find out in our valuation breakdown. Result: Price-to-book of 23.9x (OVERVALUED) However, Corvus is still loss making, reporting a net loss of $15.075m and no revenue, so any setback in its clinical trials or funding plans could quickly challenge today’s rich P/B. Find out about the key risks to this Corvus Pharmaceuticals narrative. Another view: DCF suggests a very different story The rich 23.9x P/B makes Corvus look expensive on assets, but our DCF model points the other way, with an estimated future cash flow value of $55.06 versus the current $20.46 share price. One model says stretched, the other says undervalued. Which set of assumptions do you trust more? Look into how the SWS DCF model arrives at its fair value. CRVS Discounted Cash Flow as at Feb 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Corvus Pharmaceuticals for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 52 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.  Build Your Own Corvus Pharmaceuticals Narrative If you look at the numbers and reach a different conclusion, or simply prefer to test your own assumptions, you can build a complete Corvus story yourself in just a few minutes, starting with Do it your way. A great starting point for your Corvus Pharmaceuticals research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision. Looking for more investment ideas? If Corvus has sparked your interest, do not stop there, the real edge often comes from comparing it with other opportunities that fit your style and risk tolerance.  Spot potential bargains early by scanning our list of 52 high quality undervalued stocks that combine quality fundamentals with pricing that may still be catching up. Focus on resilience first by checking out 84 resilient stocks with low risk scores, a set of companies filtered for lower risk scores that could suit a steadier approach. Hunt for future standouts by reviewing the screener containing 24 high quality undiscovered gems, where smaller, less followed names might offer something different to your current holdings.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2610663331","isCrawlerRequest":true}